We strive to put patients first and preserve their future possibilities

UroGen Pharma is planning to start the OLYMPUS trial during 2016 and is looking for centers in US and Europe. The study will evaluate  the feasibility, safety, durability and ablative effect of MMC Mixed With TCGel in patients with Upper Tract Urothelial Cancer UTUC. TheraCoat is planning to recruit an estimation of 80 patients.

Investigators interested in participating, please contact Dr Michal Jeshurun at: michalj@urogen.com